- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT01316120
Randomized Comparison of Vaginal Self Sampling for Human Papillomavirus (HPV) Testing by Standard Versus Dry Vaginal Swabs (HPVDry)
Studieoversigt
Status
Betingelser
Intervention / Behandling
Detaljeret beskrivelse
High-risk human papillomavirus (HR-HPV) infections in women are clinically important because they have been associated with nearly all cases of preinvasive and invasive cervical neoplasia1. Genital HR-HPV related infection is common, affecting approximately 10-25% of women, depending on the population and age-groups studied2-4.
With the advance in our understanding of HPV biology and the development of technologies for HPV detection together with the poor sensitivity of a single Pap test, there has been now a growing interest concerning the potential use of HPV DNA testing as a screening tool for cervical cancer5.
Currently, there is no consensus on which sampling method is the most effective for HPV DNA testing. These last years, studies have reported that samples provided by women themselves were suitable for DNA testing and support the feasibility of self-collection for HPV DNA testing6-8. Data from these studies support that it is acceptable for the women and demonstrated that a fairly high concordance rate between the self- and physicians testing method has been achieved.
Potential advantage of self-collection is that it could improve access to health care, reduce healthcare costs and save time for patients and providers. Available data have been reported with the use of specimen transport medium (STM), but the use of dry vaginal swab may potentially offer similar reliability than standard STM. Small studies suggest that HPV test (PCR) sampled by physicians using dry vaginal swab seems to be as accurate as those performed in a standard medium for HPV detection9,10. Dry vaginal swab offers potential advantages in terms of being more convenient for collection and is less expensive than a vaginal swab placed in a transport medium.
The aim of our study is to assess the performance of self-obtained v-DRY versus "standard" v-STM and its acceptability.
Undersøgelsestype
Tilmelding (Forventet)
Fase
- Ikke anvendelig
Deltagelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
Inclusion Criteria:
- 20 years or older,
- First consultation in our colposcopy unit,
- Understands study procedures and accepts voluntarily to participate by signing the informed consent form (ICF).
Exclusion Criteria:
- Previous hysterectomy,
- Pregnant,
- Virgin,
- Not able to comply with the protocol study.
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Diagnostisk
- Tildeling: Randomiseret
- Interventionel model: Enkelt gruppeopgave
- Maskning: Ingen (Åben etiket)
Våben og indgreb
Deltagergruppe / Arm |
Intervention / Behandling |
---|---|
Eksperimentel: HPV Dry first
Randomization will determine the sequence of the two tests, avoiding potential bias that may advantage the "first" test.
All specimens will be tested for the same pathogens (HR-HPV) using the same diagnostic tests
|
Instructions will be given to the patients by a research nurse and ICF will be obtained.
For specimen collection, participants will be instructed to wash their hands before the procedure.
Each participant will receive a package containing a specimen collection kit.
Recommendations will be to hold the swab by the end of the handle, to insert the swab into the vagina avoiding contact with the external genitalia, rotate 1 round and to replace the swab in a plastic sleeve (v-DRY) or in a tube containing specimen transport medium (v-STM),.
|
Eksperimentel: HPV standard transport medium
Randomization will determine the sequence of the two tests, avoiding potential bias that may advantage the "first" test.
All specimens will be tested for the same pathogens (HR-HPV) using the same diagnostic tests
|
Instructions will be given to the patients by a research nurse and ICF will be obtained.
For specimen collection, participants will be instructed to wash their hands before the procedure.
Each participant will receive a package containing a specimen collection kit.
Recommendations will be to hold the swab by the end of the handle, to insert the swab into the vagina avoiding contact with the external genitalia, rotate 1 round and to replace the swab in a plastic sleeve (v-DRY) or in a tube containing specimen transport medium (v-STM),.
|
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
---|---|---|
To assess sensibility and specificity of dry swabs for HPV diagnosis
Tidsramme: day 1
|
Agreement between collection methods in terms of HPV risk categories will be measured using the kappa statistic ( ) with a precision of 10% (95% confidence interval).
This measure of agreement is 0 when the amount of agreement is what would be expected by chance and 1 when there is perfect agreement.
|
day 1
|
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
---|---|---|
Preference about HPV self-collection
Tidsramme: day 1
|
Women will complete a self administered questionnaire on demographics and preference for sampling method (Dry versus standard)
|
day 1
|
Sensitivity and specificity of specimen transport medium (STM)
Tidsramme: day 1
|
Sensitivity and specificity to detect high-risk HPV using v-STM as gold standard will be reported.
|
day 1
|
Samarbejdspartnere og efterforskere
Sponsor
Efterforskere
- Studieleder: Patrick Petignat, Prof, HUG
Publikationer og nyttige links
Datoer for undersøgelser
Studer store datoer
Studiestart
Primær færdiggørelse (Faktiske)
Studieafslutning (Forventet)
Datoer for studieregistrering
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først opslået (Skøn)
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Skøn)
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Yderligere relevante MeSH-vilkår
Andre undersøgelses-id-numre
- HPVDry
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .
Kliniske forsøg med Human papillomavirus infektion
-
Xiamen Innovax Biotech Co., LtdAfsluttet
-
Plan A Health, IncMerck Sharp & Dohme LLCTilmelding efter invitationHuman Papillomavirus VaccinationForenede Stater
-
London School of Hygiene and Tropical MedicineMerck Sharp & Dohme LLC; Public Health England; University of CambridgeAktiv, ikke rekrutterendeHuman Papillomavirus VaccineGambia
-
Columbia UniversityNational Cancer Institute (NCI); Makerere UniversityIkke rekrutterer endnuHuman Papillomavirus VaccinationForenede Stater, Uganda
-
Washington University School of MedicineNational Cancer Institute (NCI)Aktiv, ikke rekrutterende
-
Arizona State UniversityNational Institute on Minority Health and Health Disparities (NIMHD); Adelante...Afsluttet
-
University of Texas Southwestern Medical CenterNational Cancer Institute (NCI); Southern Methodist University; Parkland...AfsluttetHuman Papillomavirus VaccinerForenede Stater
-
Indiana UniversityMerck Sharp & Dohme LLCAfsluttetHuman Papillomavirus VaccinationForenede Stater
-
Laval UniversityCenters for Disease Control and PreventionAfsluttet
-
University of PittsburghMerck Sharp & Dohme LLCAfsluttetQuadrivalent HPV Vaccine | Human Papillomavirus VaccineForenede Stater